Cuban: AI won't replace radiologists, targets admin instead

Cuban's argument rests on a straightforward cost calculation: inference fees exceed radiologist wages, and the liability and regulatory burden of clinical AI systems remain high. He does not dispute AI's technical capability; he disputes its economic rationality in high-stakes clinical settings. This framing is noteworthy because it sidesteps the usual "AI will replace X profession" narrative and instead identifies where AI creates real value in healthcare—the administrative layer that pharmacy benefit managers, insurers, and large health systems have built over decades.

The three largest PBM-owning conglomerates are already executing this vision. CVS Health, Cigna, and UnitedHealth Group have all announced AI deployments targeting claims processing, prior authorization, and clinician documentation. CVS reported that its AI-enabled claims manager will reduce processing time by over 20% and Aetna staff now spend two minutes instead of 90 minutes on case preparation. Cigna's Pharmacy Forward program cuts documentation time by up to 50%. UnitedHealth's Optum Rx reports 96% first-pass approval on digital prior authorization.

Cuban's broader point—that these administrative systems generate enterprise value and AI threatens that value—is testable through these companies' margins and revenue growth as automation spreads. Whether automation expands their reach and reduces costs (expanding margins) or simply compresses the price they can charge for administrative work (compressing margins) remains an open question for investors.